Please login to the form below

Not currently logged in
Email:
Password:

pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib , an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... The Sanofi decision was taken following reported cases consistent with Wernicke's encephalopathy in patients participating in the clinical trials. Pacritinib, an oral therapy, is

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....